GRAPE model for gastric cancer screening
Official title: Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
Run by Zhejiang Cancer Hospital · NCT07067983 · Data updated 2026-11-12
This project will test whether the GRAPE computer model can help detect gastric cancer in adults aged 18–80 who are having thoracoabdominal CT scans.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1000000 (estimated) |
| Sponsor | Zhejiang Cancer Hospital Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | May 30, 2025 |
| Main results expected | December 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 16, 2025 |
| Trial ID | NCT07067983 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 who are undergoing thoracoabdominal CT at the study site and can give written informed consent are ideal candidates.
✕Probably not a fit
People already diagnosed with gastric cancer, those unable to communicate or provide informed consent, and those outside the 18–80 age range are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational study enrolling adults aged 18–80 who undergo thoracoabdominal CT at Zhejiang Cancer Hospital. The GRAPE algorithm will be applied to systematic CT screening results to identify findings suggestive of gastric cancer. Detection rates will be recorded across different disease stages and compared with subsequent clinical diagnoses or follow-up. The study excludes people with a prior confirmed gastric cancer diagnosis and those unable to provide informed consent.
Why it matters
Potential benefit: If successful, the GRAPE model could increase early detection of gastric cancer from routine CT scans and help direct timely diagnostic follow-up.
How similar studies have gone: AI and computer models applied to medical imaging have shown promise in other cancers, but using the GRAPE model specifically for gastric cancer screening is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 18 and 80 years * Individuals undergoing thoracoabdominal CT examination * Voluntarily participated in the study and provided written informed consent Exclusion Criteria: * Patients with confirmed diagnosis of gastric cancer * Individuals with severe intellectual disabilities or communication disorders
Where it's running
-
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Xiangdong Cheng — Zhejiang Cancer Hospital
- Study coordinator: Xiangdong Cheng
- Email: chengxd@zjcc.org.cn
- Phone: 0086-571-881280
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.